NAD+ Research Overview 2026

Nicotinamide adenine dinucleotide (NAD+) is a coenzyme present in every living cell, essential for hundreds of enzymatic reactions spanning energy metabolism, DNA repair, and gene expression regulation. Its discovery as a central mediator of aging biology — through its roles as a substrate for sirtuins and PARPs — has generated one of the most active areas of longevity research over the past two decades.

Biochemistry and Cellular Roles

Beyond its redox roles, NAD+ serves as a consumed substrate for three enzyme classes with profound relevance to aging biology:

Sirtuins (SIRT1-7) — NAD-dependent protein deacylases that regulate transcription, DNA repair, mitochondrial biogenesis, and metabolic adaptation. Sirtuin activity is directly proportional to NAD+ availability — meaning cellular NAD+ decline with aging translates directly to reduced sirtuin activity and downstream epigenetic dysregulation.

PARPs (Poly-ADP ribose polymerases) — DNA repair enzymes that consume NAD+ as a substrate for ADP-ribosylation. DNA damage activates PARPs, consuming large quantities of NAD+ and potentially depleting cellular reserves — a proposed mechanism linking age-associated DNA damage accumulation to NAD+ decline.

CD38 — A NAD+ consuming enzyme whose expression increases with age and during inflammation. CD38-mediated NAD+ consumption has been characterized as a primary driver of age-associated NAD+ decline, with CD38-knockout animal models showing dramatically elevated NAD+ levels and improved metabolic function in aging.

Age-Associated NAD+ Decline

Human tissue NAD+ levels decline approximately 50% between ages 40 and 60, with the most dramatic declines in metabolically active tissues including skeletal muscle, liver, and brain. This decline has been mechanistically linked to increased PARP activity from cumulative DNA damage, increased CD38 expression during inflammaging, and reduced activity of NAD+ biosynthetic enzymes including NAMPT.

Precursor Research — NMN and NR

NMN (Nicotinamide Mononucleotide) — Enters cells via the Slc12a8 transporter and is converted to NAD+ by NMNAT enzymes. Human trials documented dose-dependent increases in blood NAD+ levels and improvements in muscle insulin sensitivity in older adults.

NR (Nicotinamide Riboside) — Phosphorylated to NMN intracellularly before conversion to NAD+. Multiple human trials documented NAD+ elevation in blood with emerging data on functional outcomes in older adults.

Direct NAD+ — Intravenous and subcutaneous administration bypasses oral bioavailability limitations. Research using direct administration documented more rapid and complete NAD+ elevation than precursor approaches, making it the subject of clinical research in contexts requiring immediate NAD+ restoration.

Published Human Research Highlights

Clinical research has documented improvements in muscle insulin sensitivity in postmenopausal women, reduced arterial stiffness in middle-aged and older adults, and improvements in gait speed and grip strength in older men. Brain NAD+ levels have been measured using phosphorus MRS in human studies, with supplementation-associated increases documented in multiple cohorts.

Research Delivery Considerations

Research protocols have examined multiple delivery routes for NAD+ and its precursors. Intravenous administration produces the most rapid plasma elevation but requires clinical infrastructure. Subcutaneous administration of NAD+ has been studied as a practical alternative for research protocols requiring direct NAD+ delivery rather than precursor conversion. Oral NMN and NR remain the most widely studied routes in human clinical trials due to practical administration considerations.

NAD+ is a research compound. Information presented is for laboratory and research reference only. For research use only per Ares Research terms.